2021-11-10T19:59:27-06:00 2021-06-30 930900579 MCDONALD JACOBS PC 520 SW YAMHILL ST STE 500 PORTLAND OR 97204 990 2020-07-01 930571472 NATIONAL PSORIASIS FOUNDATION NATI 5032447404 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 RANDY BERANEK PRESIDENT/CEO 5032447404 2021-11-09 1 RANDY BERANEK 999009999 SANG AHN P00540880 5032270581 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z RANDY BERANEK 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 20088816 0 X WWW.PSORIASIS.ORG X 1968 OR TO DRIVE EFFORTS TO CURE PSORIATIC DISEASE AND IMPROVE THE LIVES OF THOSE AFFECTED. 17 17 71 2160 1215819 336705 12708368 11146561 1493367 1228158 218630 367378 -183715 -84431 14236650 12657666 3264997 2809557 0 0 6390459 5444914 0 203911 1763556 4249222 2671352 13904678 11129734 331972 1527932 14435005 15989040 5710733 5053003 8724272 10936037 X THE NATIONAL PSORIASIS FOUNDATION PROVIDES PEOPLE WITH PSORIASIS AND PSORIATIC ARTHRITIS THE SERVICES THEY NEED TO BEST MANAGE THEIR CONDITION, WHILE PROMOTING RESEARCH TO FIND A CURE. 0 0 3700927 2809557 647 RESEARCHNPF CONTINUED TO LEAD COLLABORATIVE, TRANSFORMATIONAL RESEARCH BY ENSURING THAT FUNDING EXTRAMURAL RESEARCH REMAINED A PRIORITY. NPF ALSO CONDUCTED RESEARCH FOR THE COMMUNITY IMPACTED BY PSORIATIC DISEASE. PSORIATIC DISEASE RESEARCH ACCOUNTED FOR 34% OF TOTAL NPF EXPENSES IN FY21. THIS INCLUDED THE COMPETITIVE RENEWAL OF THE PSA DIAGNOSTIC TEST GRANT WITH FUNDING DEDICATED TO THE DEVELOPMENT OF A DIAGNOSTIC TEST FOR PSORIATIC ARTHRITIS (PSA), NPF SUCCESSFULLY LAUNCHED THE MORE THAN SKIN DEEP MENTAL HEALTH GRANT, WHICH FUNDS RESEARCH AIMED AT ADDRESSING MENTAL HEALTH ISSUES, A MAJOR PSORIATIC DISEASE COMORBIDITY. COMPETITIVE RENEWAL OF THE PSORIASIS PREVENTION INITIATIVE GRANTS OCCURRED. THESE GRANTS SUPPORT PROJECTS FROM MULTI-INSTITUTIONAL, MULTI-DISCIPLINARY TEAMS WITH THE GOAL OF IDENTIFYING AN INTERVENTION THAT WILL PREVENT THE ONSET OF PSORIATIC DISEASE, DISEASE RELAPSE, OR RELEVANT COMORBIDITIES. THE NPF RESEARCH TEAM PUBLISHED SEVERAL ABSTRACTS AND PAPERS AND BROUGHT THE INTERNALLY GENERATED DATA TO THE COMMUNITY. THEY ALSO LED A SUCCESSFUL EFFORT TO PUBLISH AN INFOGRAPHIC TO EDUCATE OTHERS ABOUT PSORIASIS BEING A SYSTEMIC, IMMUNE-MEDIATED DISEASE WITH SEVERAL COMORBIDITIES IMPACTING OVERALL HEALTH OUTCOMES. NPF HOSTED A RESEARCH SESSION IN CONJUNCTION WITH THE SOCIETY OF INVESTIGATIVE DERMATOLOGY. THE CITIZEN PSCIENTIST, AN ON-LINE PATIENT REGISTRY PLATFORM, WAS VALIDATED, AND THE PEER REVIEWED PUBLICATION THAT NPF OVERSEES, THE JOURNAL OF PSORIASIS AND PSORIATIC ARTHRITIS, DOUBLED THE NUMBER OF ORIGINAL RESEARCH SUBMISSIONS. IN PARTNERSHIP WITH OTHER NPF FUNCTIONAL TEAMS, A GRANT WAS SUBMITTED TO THE CENTERS FOR DISEASE CONTROL WITH THE GOAL OF RAISING AWARENESS AND EDUCATING HEALTHCARE WORKERS ABOUT PSORIATIC DISEASE. IN COLLABORATION WITH THOUGHT LEADERS AND STAKEHOLDERS, NPF WAS INSTRUMENTAL IN THE INCLUSION OF PSORIATIC DISEASE IN THE ACCELERATED MEDICINES PARTNERSHIP FOR AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES, A PUBLIC/PRIVATE PARTNERSHIP WHICH WILL BRING MILLIONS OF DOLLARS TO RESEARCH OVER THE NEXT 5 YEARS. 652225 MEDICAL PROFESSIONAL EDUCATIONTHE MAJORITY OF NPF PROGRAMS WERE HELD VIRTUALLY, DUE TO THE ONGOING COVID-19 PANDEMIC. THE NPF MEDICAL AFFAIRS TEAM SUCCESSFULLY DEVELOPED NEW APPROACHES TO ENSURE ENGAGEMENT AND TO BEST MEET THE EDUCATIONAL NEEDS OF PROVIDERS AT EVERY STAGE OF THEIR CAREER. THE NPF COVID-19 TASK FORCE CONTINUED TO OFFER UPDATED DATA-BASED GUIDANCE STATEMENTS FOR NPF, PROVIDERS, AND THE COMMUNITY. THE TASK FORCE IS A MULTIDISCIPLINARY GROUP OF PROVIDERS CHARGED WITH CLOSELY MONITORING THE EMERGING DATA AND PROVIDING GUIDANCE ON THE RISKS OF COVID-19, THE ADVANCEMENTS IN TREATMENTS, AND VACCINATION CONSIDERATIONS FOR THOSE LIVING WITH PSORIATIC DISEASE. NPF CONTINUED TO FOCUS EFFORTS ON COLLABORATION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS, WHICH IS ESSENTIAL TO IMPROVE THE DIAGNOSIS AND TREATMENT OF PSA. NPF ALSO INCORPORATED A FOCUS ON COLLABORATIVE CARE BETWEEN ALL PROVIDERS WITHIN A PRACTICE, PARTICULARLY ADVANCED PROVIDERS AND OTHER SPECIALTIES SUCH AS CARDIOLOGISTS. THE VIRTUAL GRAND ROUNDS PROGRAM WAS VERY POPULAR, AS WAS THE ADVANCE PRACTICE PSORIASIS RECOGNITION PROGRAM, WHICH IS SPECIFICALLY DESIGNED TO ADDRESS KNOWLEDGE AND PRACTICE GAPS AMONG PHYSICIAN ASSISTANTS AND NURSE PRACTITIONERS. THE SUCCESSFUL 23RD ANNUAL NPF RESIDENTS MEETING WAS HELD VIRTUALLY. NPF COMPLETED AN EDUCATIONAL PROGRAM AIMED AT MEDICAL SCHOOLS TO HELP STUDENTS GAIN A DEEPER UNDERSTANDING OF PSORIATIC DISEASE. THIS PROGRAM WILL BE PROVIDED TO MEDICAL SCHOOLS IN FY22 TO ENSURE PSORIASIS IS INCLUDED IN THE VERY LIMITED DERMATOLOGY CURRICULA. NPF HELD AN INAUGURAL PAYER EDUCATION PROGRAM. ACCESS TO THE EFFECTIVE AND SAFE TREATMENTS IS CRITICAL AND HAVING INSURERS UNDERSTAND PSORIATIC DISEASE IS IMPERATIVE TO PROPER FORMULARY DEVELOPMENT AND APPROVALS. 856730 ADVOCACYNPF WORKED TO ENSURE PATIENTS HAVE AFFORDABLE ACCESS TO THE TREATMENTS THEY NEED, INCLUDING LEGISLATION TO ADDRESS HARMFUL COPAY ACCUMULATOR ADJUSTMENT PROGRAMS. NPF SUCCESSFULLY WORKED TO PASS LEGISLATION ADDRESSING THESE PROGRAMS IN SEVERAL STATES. AS OF OCT. 2021, 12 STATES HAVE NOW PROTECTED PATIENTS FROM THESE PROGRAMS. NPF WAS INSTRUMENTAL IN STEP THERAPY REFORM VICTORIES IN OREGON, NEBRASKA, AND ARKANSAS. AS OF OCT. 2021, NPF BEEN A PART OF STEP THERAPY IN 29 STATES. NPF HAS INCREASED SUPPORT FOR FEDERAL STEP THERAPY LEGISLATION TO LEVELS NOT PREVIOUSLY SEEN AND HAS BEEN A LEADING VOICE ON THE PREPONDERANCE OF TELEHEALTH DURING THE COVID PANDEMIC. NPF ALSO LEVERAGED TENS OF THOUSANDS OF ADVOCATES TO WORK FOR HEALTH INSURANCE COVERAGE IMPROVEMENTS FOR THE MILLIONS OF PEOPLE LIVING WITH PSORIATIC DISEASE, WHILE ALSO WORKING TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSA TREATMENTS AND INCREASING FEDERAL FUNDING FOR PSORIATIC DISEASE RESEARCH. 3111596 14817 EDUCATION, OUTREACH AND PATIENT SERVICESTHROUGH THE NPF PATIENT NAVIGATION CENTER, ALMOST 16,000 PATIENTS RECEIVED FREE, PERSONALIZED SUPPORT DESIGNED TO HELP THEM UNDERSTAND PSORIATIC DISEASE AND TREATMENT OPTIONS, NAVIGATE INSURANCE CHALLENGES, AND FIND THE APPROPRIATE HEALTH CARE PROVIDER. THE PATIENT NAVIGATION CENTER PROVIDED RESOURCES TO HELP PEOPLE COPE WITH THE IMPACT OF COVID-19 ON THEIR PSORIATIC DISEASE. NPF ADVANCE MAGAZINE CONTINUED TO PROVIDE THE LATEST INFORMATION, STORIES, AND RESOURCES FIVE TIMES ANNUALLY FOR OVER 21,000 PRINT SUBSCRIBERS AND HUNDREDS OF THOUSANDS OF ONLINE READERS. NPF PROVIDED A COMPREHENSIVE SET OF EDUCATIONAL AND INFORMATIONAL RESOURCES TO THE 4,085,982 VISITORS TO PSORIASIS.ORG AND ASSOCIATED SITES. EACH WEEK, MORE THAN 138,000 PEOPLE RECEIVED ADVANCE WEEKLY, THE OFFICIAL PATIENT-FOCUSED E-NEWSLETTER OF NPF.NPF INTERACTED WITH OVER 135,000 PEOPLE FROM THE COMMUNITY ON SOCIAL MEDIA CHANNELS (FACEBOOK, TWITTER, INSTAGRAM, LINKEDIN) THROUGH TEAM NPF, 1,974 PEOPLE PARTICIPATED IN AN IN-PERSON OR VIRTUAL EVENT. EVENTS INCLUDED PSTAMP OUT (BINGO), CYCLE, RUN, WALK, AND DIY FUNDRAISERS. 3111596 14817 8321478 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 85 0 71 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X JOHN ROGACKI 5032447404 6600 SW 92ND AVENUE NO 300 PORTLAND OR 97223 RON GRAU CHAIR 1.00 X X 0 0 0 CAROL OSTROW CHAIR-ELECT 1.00 X X 0 0 0 EYAL OFIR VICE CHAIR 1.00 X X 0 0 0 MIKE REFERMAT TREASURER 1.00 X X 0 0 0 RICHARD SEIDEN SECRETARY 1.00 X X 0 0 0 RAYMOND CHIP NEWTON IMMEDIATE PAST CHAIR 1.00 X 0 0 0 APRIL ARMSTRONG MD DIRECTOR 1.00 X 0 0 0 MATTHEW T KISELICA DIRECTOR 1.00 X 0 0 0 PETE MILLER DIRECTOR 1.00 X 0 0 0 JASON LICHTEN MD DIRECTOR 1.00 X 0 0 0 MARK OBERMAN DIRECTOR 1.00 X 0 0 0 MICHAEL GRAFF DIRECTOR 1.00 X 0 0 0 ELAINE HUSNI MD DIRECTOR 1.00 X 0 0 0 JERRY BAGEL MD DIRECTOR 1.00 X 0 0 0 JODI WOOD DIRECTOR 1.00 X 0 0 0 LARRY GREEN MD DIRECTOR 1.00 X 0 0 0 JONATHAN SCOTT DIRECTOR 1.00 X 0 0 0 RANDY BERANEK PRESIDENT/CEO 40.00 X 558757 0 28649 JOHN ROGACKI VICE PRESIDENT OF FINANCE & OPERATIONS 40.00 X 193722 0 15766 LEAH HOWARD CHIEF OPERATING OFFICER 40.00 X 311468 0 17874 EMILY BOYD CHIEF REVENUE OFFICER 40.00 X 212190 0 20547 STACY BELL CHIEF SCIENTIFIC AND MEDICAL OFFICER 40.00 X 216769 0 28346 PATRICK STONE VP OF GOVERNMENT RELATIONS & ADVOCACY 40.00 X 133652 0 7537 KRISTINE BOCKMIER VICE PRESIDENT OF FIELD OPERATIONS 40.00 X 126661 0 15584 1753219 0 134303 7 0 1 0 BENTZ WHALEY FLESSNER AND ASSOCIATES IN 7900 XERXES AVE SOUTH SUITE 980 MINNEAPOLIS MD 55431 FUNDRAISING CONSULTING AND MAILINGS 241754 CONVERO 835 SHARON DRIVE SUITE 200 CLEVELAND DC 44145 PUBLICATION DEVELOPMENT AND DISTRIBUTION 194668 SMITH & CONNORS LLC 1429 SE 52ND AVE PORTLAND OR 97215 WEBSITE REDESIGN 173966 FAEGRE DRINKER BIDDLE & REATH LLP 1050 K STREET NW SUITE 400 WASHINGTON DC 20001 CONSULTING 116999 4 69420 46450 1660202 825046 8545443 122718 11146561 ADVERTISING INCOME 541800 1215819 1215819 CONSULTING 532000 11692 11692 ONFERENCE REGISTRATION 611710 647 647 1228158 164668 164668 7546304 7343594 202710 202710 202710 0 1660202 87556 -87556 -87556 3125 0 3125 3125 12657666 15464 1215819 279822 1899557 1899557 910000 910000 956592 673496 78042 205054 3573859 2516204 291568 766087 176032 123937 14361 37734 420850 296303 34334 90213 317581 223596 25909 68076 54660 37134 7245 10281 19550 19550 199263 199263 203911 203911 37146 37146 664617 485763 114098 64756 444641 232668 45701 166272 382263 224425 107503 50335 167274 124133 16402 26739 55648 39526 4361 11761 BAD DEBT 316512 150117 116567 49828 TAXES 101683 101683 228095 185356 30230 12509 11129734 8321478 1044700 1763556 X 4485112 4976495 2866371 1043672 337482 470405 14453 9541 265591 239985 506681 372901 170343 133780 6265489 9084998 30164 30164 14435005 15989040 1029652 844518 3270000 2861131 182500 210437 1228581 1136917 5710733 5053003 X 7256310 9837008 1467962 1099029 8724272 10936037 14435005 15989040 1527932 825521 -141688 0 X X 0 1 X 1 0 X 13602330 13408527 13168307 12708368 11146561 64034093 13602330 13408527 13168307 12708368 11146561 64034093 24378033 39656060 62020 89858 124320 216849 164668 657715 539039 637300 1116715 1291031 1065032 4649117 69340925 4156158 0.57190 0.58820 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 25348 173915 199263 9129769 9329032 616452 154113 0 0 722412 711673 744630 616452 2795167 4192751 464205 430252 448606 199263 1542326 180603 177918 186158 154113 698792 1048188 14589 18486 25348 58423 32132 23681 8451 354686 321898 32788 119863 27322 92541 133780 DEFERRED RENT 72595 GIFT ANNUITY LIABILITY 33685 REFUNDABLE ADVANCE 1030637 1136917 X 13446041 825521 825521 12620520 37146 37146 12657666 11092588 0 11092588 37146 37146 11129734 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISION OF FASB ASC TOPIC OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND CONCLUDED THAT THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS TOPIC. 1 0 0 0 0 0 0 0 0 0 SPAIN EARLY CAREER RESEARCH GRANT 50000 BANK DRAFT OR COMPUTER CHECK SPAIN TRANSLATIONAL RESEARCH GRANT - 2ND YEAR 100000 BANK DRAFT OR COMPUTER CHECK SWEDEN DISCOVERY GRANT 75000 BANK DRAFT OR COMPUTER CHECK UK TRANSLATIONAL RESEARCH GRANT - 2ND YEAR 100000 BANK DRAFT OR COMPUTER CHECK AUSTRALIA MILESTONES TO A CURE 100000 BANK DRAFT OR COMPUTER CHECK IRELAND EARLY CAREER RESEARCH GRANT 50000 BANK DRAFT OR COMPUTER CHECK CANADA PSA DIAGNOSTIC TEST GRANT FOR $300,000, DISCOVERY GRANT FOR $75,000, SUMMER STUDENT RESEARCH GRANT - $5,000 380000 BANK DRAFT OR COMPUTER CHECK BELGIUM EARLY CAREER RESEARCH GRANT 50000 BANK DRAFT OR COMPUTER CHECK 8 0 0 0 0 0 0 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE VP OF RESEARCH PROGRAMS OF THE NATIONAL PSORIASIS FOUNDATION. PART III ACCOUNTING METHOD: X X X X X X 1 BENTZ WHALEY FLESSNER AND ASSOCIATES INC 7900 XERXES AVENUE SOUTH SUITE 980 MINNEAPOLIS MN 55431 FUNDRAISING CONSULTING AND MAILING SERVICES 0 0 203911 -203911 203911 -203911 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY TEAM NPF 1273841 1273841 24765 7175 17831 490 5909 ST LOUIS GALA 337025 337025 1064 1 49336 49336 8319 20676 300 1027 1660202 1660202 24765 15494 38507 790 8000 87556 -87556 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 022155491 042103881 501 (C)(3) 50000 PSORIATIC DISEASE RESEARCH FELLOWSHIP CLEVELAND CLINIC FOUNDATION 6801 BRECKSVILLE RD RK1-85 INDEPENDENCE OH 441315032 912153073 501 (C)(3) 100000 MORE THAN SKIN DEEP: MENTAL HEALTH NATIONAL INSTITUTES OF HEALTH NIAID 5601 FISHERS LN STE 6D MSC 980 ROCKVILLE MD 20852 520858115 170(C)(1) 100000 TRANSLATIONAL RESEARCH GRANT - YEAR 2 NEW YORK UNIVERSITY SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022415026 135562308 501 (C)(3) 100000 MORE THAN SKIN DEEP: MENTAL HEALTH NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE 633 CLARK ST ROOM G-547 EVANSTON IL 60208 362167817 501 (C)(3) 50000 PSORIATIC DISEASE RESEARCH FELLOWSHIP NYU LANGONE 550 FIRST AVE NEW YORK NY 100166402 133971298 501 (C)(3) 350000 PSA DIAGNOSTIC TEST GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (UNIVERSITY OF CALIFORNIA DAVIS PO BOX 989062 WEST SACRAMENTO CA 957989062 946036494 501 (C)(3) 275000 BRIDGE GRANT AND TRANSLATIONAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO (CONTRACTS & GRA 1855 FOLSOM ST STE 425 SAN FRANCISCO CA 94143 946036493 501 (C)(3) 230000 PSORIATIC DISEASE RESEARCH FELLOWSHIP THE REGENTS OF THE UNIVERSITY OF MICHIGAN 1910 TAUBMAN CENTER ANN ARBOR MI 48109 386006309 501 (C)(3) 100000 TRANSLATIONAL RESEARCH GRANT - YEAR 1 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3542 WALNUT ST ROOM P-221 PHILADELPHIA PA 19178 231352685 501 (C)(3) 155000 PSORIATIC DISEASE RESEARCH FELLOWSHIP UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER 11100 EUCLID AVENUE CLEVELAND OH 44106 341567805 501 (C)(3) 150000 PSORIATIC DISEASE RESEARCH FELLOWSHIP UNIVERSITY OF PITTSBURGH 500 ROSS ST 154-0455 PITTSBURGH PA 15262 250965591 501 (C)(3) 50000 EARLY CAREER RESEARCH GRANT UNIVERSITY OF ROCHESTER 500 ROSS ST 154-0455 ROCHESTER NY 14642 160743209 501 (C)(3) 75000 DISCOVERY GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA ST STE 102 LOS ANGELES CA 900898001 951642394 501 (C)(3) 50000 PSORIATIC DISEASE RESEARCH FELLOWSHIP WASHINGTON UNIVERSITY SCHOOL OF MEDICINE 700 ROSEDALE AVE CB 1034 ST LOUIS MO 631121408 430653611 501 (C)(3) 75000 DISCOVERY GRANT 15 1 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND FISCAL PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE SENIOR VP OF RESEARCH PROGRAMS OF THE NATIONAL PSORIASIS FOUNDATION. X X X X 0 1 0 1 0 1 0 1 0 RANDY BERANEK PRESIDENT/CEO 320019 0 41715 0 197023 0 14250 0 14399 0 587406 0 0 0 LEAH HOWARD CHIEF OPERATING OFFICER 202996 0 15210 0 93262 0 10530 0 7344 0 329342 0 0 0 STACY BELL CHIEF SCIENTIFIC AND MEDICAL OFFICER 206769 0 10000 0 0 0 10339 0 18007 0 245115 0 0 0 EMILY BOYD CHIEF REVENUE OFFICER 197899 0 14291 0 0 0 9894 0 10653 0 232737 0 0 0 JOHN ROGACKI VICE PRESIDENT OF FINANCE & OPERATIO 176559 0 17163 0 0 0 7038 0 8728 0 209488 0 0 0 PART I, LINE 4B CHANGE OF CONTROL PAYMENT: - NONE PAID OUT 5-YEAR 457(F) DEFERRED COMPENSATION PLAN: RANDY BERANEK - $197,023,10 LEAH HOWARD - $93,262.34 EMPLOYER CONTRIBUTIONS TO 401K: FOR THE CALENDAR YEAR: RANDY BERANEK - $14,250 JOHN ROGACKI - $7,038.39 LEAH HOWARD - $10,530 EMILY BOYD - $9,893.88 STACY BELL - $10,338.58 PATRICK STONE - $6,556.41 KRISTINE BOCKMIER - $6,212.43 PART I, LINE 5 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF THE COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES (50%), THE NPF MEETING ITS ANNUAL REVENUE TARGET (25%) AND THE NPF MEETING ITS NET SURPLUS TARGET (25%). ALL STAFF ARE INCLUDED IN THE INCENTIVE PLAN AT 1% BASED ON REVENUE AND 1% BASED ON NET SURPLUS. PART I, LINE 6 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF THE COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES (50%), THE NPF MEETING ITS ANNUAL REVENUE TARGET (25%) AND THE NPF MEETING ITS NET SURPLUS TARGET (25%). ALL STAFF ARE INCLUDED IN THE INCENTIVE PLAN AT 1% BASED ON REVENUE AND 1% BASED ON NET SURPLUS. PART I, LINE 7 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF THE COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES (50%), THE NPF MEETING ITS ANNUAL REVENUE TARGET (25%) AND THE NPF MEETING ITS NET SURPLUS TARGET (25%). ALL STAFF ARE INCLUDED IN THE INCENTIVE PLAN AT 1% BASED ON REVENUE AND 1% BASED ON NET SURPLUS. X 2 122718 FMV ON THE DATE RECEIVED 0 1 1 PART I, COLUMN (B): NUMBER OF CONTRIBUTORS PART I, LINE 32B: THE ORGANIZATION USES AN OUTSIDE COMPANY THAT RECEIVES DONATED AUTOMOBILES AND SELLS THEM ON BEHALF OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS EMAILED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO ITS BEING FILED ELECTRONICALLY WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C WE HAVE A CONFLICT OF INTEREST POLICY THAT IS SIGNED BY ALL DIRECTORS ANUALLY. ALL DIRECTORS AND KEY EMPLOYEES REFRAIN FROM VOTING OR COMMENTING ON ANYTHING WHERE THERE COULD BE A CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS ANNUALLY REVEIWS AND APPROVES THE CEO'S COMPENSATION. THE FOUNDATION UTILIZES AN INDEPENDENT COMPENSATION CONSULTANT AND SUBSCRIBES TO A SALARY SURVEY FOR COMPARABLE INFORMATION FOR SALARIES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. AUDTIED FINANCIAL STATEMENTS ARE ALSO DISPLAYED ON THE WEBSITE. FORM 990, PART XII, LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.